IBDEI0QL ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,13075,2)
 ;;=^123854
 ;;^UTILITY(U,$J,358.3,13076,0)
 ;;=580.9^^78^815^1
 ;;^UTILITY(U,$J,358.3,13076,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,13076,1,1,0)
 ;;=1^580.9
 ;;^UTILITY(U,$J,358.3,13076,1,2,0)
 ;;=2^ACUTE GLOMERULONEPHRITIS
 ;;^UTILITY(U,$J,358.3,13076,2)
 ;;=^270342
 ;;^UTILITY(U,$J,358.3,13077,0)
 ;;=584.9^^78^815^2
 ;;^UTILITY(U,$J,358.3,13077,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,13077,1,1,0)
 ;;=1^584.9
 ;;^UTILITY(U,$J,358.3,13077,1,2,0)
 ;;=2^ACUTE RENAL FAILURE
 ;;^UTILITY(U,$J,358.3,13077,2)
 ;;=^338532
 ;;^UTILITY(U,$J,358.3,13078,0)
 ;;=582.9^^78^815^3
 ;;^UTILITY(U,$J,358.3,13078,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,13078,1,1,0)
 ;;=1^582.9
 ;;^UTILITY(U,$J,358.3,13078,1,2,0)
 ;;=2^CHRONIC GLOMERULONEPHRITIS
 ;;^UTILITY(U,$J,358.3,13078,2)
 ;;=^270351
 ;;^UTILITY(U,$J,358.3,13079,0)
 ;;=585.9^^78^815^4
 ;;^UTILITY(U,$J,358.3,13079,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,13079,1,1,0)
 ;;=1^585.9
 ;;^UTILITY(U,$J,358.3,13079,1,2,0)
 ;;=2^CHRONIC KIDNEY DISEASE
 ;;^UTILITY(U,$J,358.3,13079,2)
 ;;=^332812
 ;;^UTILITY(U,$J,358.3,13080,0)
 ;;=586.^^78^815^5
 ;;^UTILITY(U,$J,358.3,13080,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,13080,1,1,0)
 ;;=1^586.
 ;;^UTILITY(U,$J,358.3,13080,1,2,0)
 ;;=2^OTHER RENAL FAILURE
 ;;^UTILITY(U,$J,358.3,13080,2)
 ;;=^104733
 ;;^UTILITY(U,$J,358.3,13081,0)
 ;;=694.9^^78^816^1
 ;;^UTILITY(U,$J,358.3,13081,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,13081,1,1,0)
 ;;=1^694.9
 ;;^UTILITY(U,$J,358.3,13081,1,2,0)
 ;;=2^BULLOUS DERMATOSES NOS
 ;;^UTILITY(U,$J,358.3,13081,2)
 ;;=^187900
 ;;^UTILITY(U,$J,358.3,13082,0)
 ;;=695.10^^78^816^2
 ;;^UTILITY(U,$J,358.3,13082,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,13082,1,1,0)
 ;;=1^695.10
 ;;^UTILITY(U,$J,358.3,13082,1,2,0)
 ;;=2^ERYTHEMA MULTIFORME NOS
 ;;^UTILITY(U,$J,358.3,13082,2)
 ;;=^336759
 ;;^UTILITY(U,$J,358.3,13083,0)
 ;;=696.1^^78^816^3
 ;;^UTILITY(U,$J,358.3,13083,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,13083,1,1,0)
 ;;=1^696.1
 ;;^UTILITY(U,$J,358.3,13083,1,2,0)
 ;;=2^PSORIASIS
 ;;^UTILITY(U,$J,358.3,13083,2)
 ;;=^271917
 ;;^UTILITY(U,$J,358.3,13084,0)
 ;;=695.81^^78^816^4
 ;;^UTILITY(U,$J,358.3,13084,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,13084,1,1,0)
 ;;=1^695.81
 ;;^UTILITY(U,$J,358.3,13084,1,2,0)
 ;;=2^STAPHLYCOCCAL SCALED SKIN SYND
 ;;^UTILITY(U,$J,358.3,13084,2)
 ;;=^113858
 ;;^UTILITY(U,$J,358.3,13085,0)
 ;;=695.13^^78^816^5
 ;;^UTILITY(U,$J,358.3,13085,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,13085,1,1,0)
 ;;=1^695.13
 ;;^UTILITY(U,$J,358.3,13085,1,2,0)
 ;;=2^STEVENS-JOHNSON SYNDROME
 ;;^UTILITY(U,$J,358.3,13085,2)
 ;;=^336636
 ;;^UTILITY(U,$J,358.3,13086,0)
 ;;=695.15^^78^816^6
 ;;^UTILITY(U,$J,358.3,13086,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,13086,1,1,0)
 ;;=1^695.15
 ;;^UTILITY(U,$J,358.3,13086,1,2,0)
 ;;=2^TOXIC EPIDRML NECROLYSIS
 ;;^UTILITY(U,$J,358.3,13086,2)
 ;;=^336638
 ;;^UTILITY(U,$J,358.3,13087,0)
 ;;=695.9^^78^816^7
 ;;^UTILITY(U,$J,358.3,13087,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,13087,1,1,0)
 ;;=1^695.9
 ;;^UTILITY(U,$J,358.3,13087,1,2,0)
 ;;=2^OTHER ERYTHEMATOUS SKIN COND
 ;;^UTILITY(U,$J,358.3,13087,2)
 ;;=^123902
 ;;^UTILITY(U,$J,358.3,13088,0)
 ;;=441.9^^78^817^2
 ;;^UTILITY(U,$J,358.3,13088,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,13088,1,1,0)
 ;;=1^441.9
 ;;^UTILITY(U,$J,358.3,13088,1,2,0)
 ;;=2^ANEURYSM,AORTIC W/O RUPTURE
 ;;^UTILITY(U,$J,358.3,13088,2)
 ;;=^9277
 ;;^UTILITY(U,$J,358.3,13089,0)
 ;;=442.9^^78^817^3
 ;;^UTILITY(U,$J,358.3,13089,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,13089,1,1,0)
 ;;=1^442.9
